Articles tagged with: ASH 2012 Meeting
Results from a Phase 1 study indicate that tabalumab in combination with Velcade demonstrates both efficacy and safety in myeloma patients who have relapsed after several previous therapies.
Dr. Nooper Raje from Massachusetts General Hospital in Boston presented the results of the study at the American Society of Hematology (ASH) annual meeting earlier this month. She explained that tabalumab was very promising in this particular patient population, and added that “this was a very well tolerated regimen.”
However, Dr. Raje emphasized that further study of tabalumab at higher doses and …
This year’s meeting of the American Society of Hematology (ASH) was held December 8 through 11 in Atlanta.
During the meeting, The Beacon published daily updates that provided overviews of the important multiple myeloma findings presented during the meeting. After the meeting concluded, The Beacon began publishing in-depth articles about the key research findings.
This article, however, shifts the focus to the bigger picture: What were the key findings of the meeting? Were there results with immediate implications for the treatment of multiple myeloma? Did …
Results from a Phase 1/2 study show that dinaciclib has anti-myeloma activity in relapsed multiple myeloma patients.
“The current study shows encouraging potential for the single-agent [use of dinaciclib] in patients with relapsed multiple myeloma,” said Dr. Shaji Kumar from the Mayo Clinic, who presented the results at the American Society of Hematology (ASH) meeting last week. He added that the treatment was also “well-tolerated with toxicity that was manageable.”
However, Dr. Kumar explained that further studies are needed to determine an optimal dosing schedule and to evaluate dinaciclib in …
Results from three Chinese clinical trials indicate that the investigational drug circularly permuted TRAIL may be effective alone or in combination with thalidomide in relapsed and refractory multiple myeloma patients.
However, further testing of the drug is necessary to determine its optimal dose.
Dr. Wenming Chen from the Chaoyang Hospital of Capital Medical University in Beijing presented the findings from the three studies last week at the American Society of Hematology (ASH) annual meeting in Atlanta.
Circularly Permuted TRAIL (CPT) is being developed by Beijing Sunbio Biotech as a treatment …
ARRY-520 is one of several potential new anti-myeloma agents that was highlighted at the American Society of Hematology (ASH) annual meeting earlier this week.
Initial results from two clinical trials show promise for ARRY-520 (filanesib), alone or in combination with other myeloma drugs, as a therapeutic option for heavily pretreated multiple myeloma patients.
“ARRY-520 shows promising activity in combination with dexamethasone in heavily pretreated myeloma patients,” said Dr. Jatin Shah, from the MD Anderson Cancer Center in Houston and lead investigator of both studies.
Based on their findings, the …